Step Therapy And Why The Cheaper Drug Comes First

A prescription can be lawful, appropriate and still refused because the plan requires a different medicine to be tried first. That requirement is step therapy, and it operates through the pharmacy benefit rather than the medical one.

The mechanism behind the requirement

The insurer designates one or more preferred agents for a condition and declines to fund alternatives until the record shows the preferred option failed or could not be tolerated.

Preference is driven partly by clinical evidence and partly by negotiated pricing, including rebates that make a nominally expensive drug cheaper to the plan than a rival.

Because rebate arrangements shift, a formulary's preferred agent can change between plan years even where the underlying clinical evidence has not moved at all.

What counts as a failed step

Failure has a documented meaning: an adequate trial at an adequate dose for an adequate duration, with a recorded lack of response or an adverse effect.

A trial that stopped early, or one recorded only as the patient disliking the medicine, frequently does not satisfy the criterion even when discontinuation was clinically sound.

Trials that happened under a previous insurer often count, but only if the records or pharmacy history can be produced. Institutional memory does not follow the patient automatically.

The exception pathway

Every step therapy programme of any regulatory standing has an exception route, and most disputes are resolved there rather than through a formal appeal.

Typical grounds include a contraindication to the preferred agent, an expectation that it will be ineffective given the patient's history, or current stability on the requested drug.

Exception requests are decided against criteria in the same way as prior authorisation, so a prescriber's letter that addresses the criteria directly does more than one that argues generally.

Where the policy interacts with continuity

A patient already stable on a medicine can be caught by step therapy at renewal, when a formulary change reclassifies the drug and the plan asks for a step that was never needed.

Many jurisdictions restrict this, requiring continuation for patients already established on a therapy, but the protections are uneven and often depend on how the plan is regulated.

Where no protection applies, the practical remedy is the exception process with documentation of established stability, which is a recognised clinical basis in most criteria sets.

Why timing decides the outcome

Step therapy determinations run to regulatory clocks, with shorter deadlines for urgent requests where delay would seriously jeopardise health.

Flagging urgency accurately at the outset changes the timetable substantially, and an urgent request that is not marked as such simply joins the standard queue.

Programme rules, protections for stable patients and decision deadlines vary by jurisdiction and change over time, so the plan documents in force determine what applies.